Skip to main content
. Author manuscript; available in PMC: 2016 Feb 8.
Published in final edited form as: J Bone Miner Res. 2013 Jan;28(1):92–107. doi: 10.1002/jbmr.1732

Fig. 1.

Fig. 1

Acute systemic administration of CB2 receptor agonist JWH015 attenuates breast (66.1) cancer–induced spontaneous and evoked pain on day 14 after femoral inoculation (time 0). Bone cancer–induced spontaneous (A) flinches (B) guarding, and (C) evoked paw withdrawal were all significantly attenuated in a time-related fashion in animals administered JWH015 (i.p.) compared to vehicle-treated animals (p ≤ 0.05; n = 15 mice per group).